Report of two cases of pseudoprogression in patients with non-small cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression

被引：65

作者：

Tanizaki, Junko ^{[1
]}

Hayashi, Hidetoshi ^{[1
]}

Kimura, Masatomo ^{[2
]}

Tanaka, Kaoru ^{[1
]}

Takeda, Masayuki ^{[1
]}

Shimizu, Shigeki ^{[2
]}

Ito, Akihiko ^{[2
]}

Nakagawa, Kazuhiko ^{[1
]}

机构：

[1] Kindai Univ, Fac Med, Dept Med Oncol, 377-2 Ohno Higashi, Osaka, Osaka 5898511, Japan

[2] Kindai Univ, Fac Med, Dept Pathol, 377-2 Ohno Higashi, Osaka, Osaka 5898511, Japan

来源：

LUNG CANCER | 2016年 / 102卷

关键词：

Pseudoprogression; Nivolumab; Non-small cell lung cancer; Adenocarcinoma; IMMUNE-RELATED RESPONSE; SOLID TUMORS; CARCINOEMBRYONIC ANTIGEN; CRITERIA; PEMBROLIZUMAB; GUIDELINES; DOCETAXEL; BLOCKADE;

D O I：

10.1016/j.lungcan.2016.10.014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The recent approval of nivolumab and other immune-checkpoint inhibitors for the treatment of certain solid tumors including non small cell lung cancer (NSCLC) has transformed cancer therapy. However, it will be important to characterize effects of such agents not seen with classical cytotoxic drugs or other targeted therapeutics. We here report two cases of NSCLC showing so-called pseudoprogression during nivolumab treatment. In both cases, imaging assessment revealed that liver metastatic lesions initially progressed but subsequently shrank during continuous nivolumab administration, with treatment also resulting in a decline in serum levels of carcinoembryonic antigen. Histological evaluation of the liver metastatic lesion of one case after regression revealed fibrotic tissue containing infiltrated lymphocytes positive for CD3, CD4, or CD8 but no viable tumor cells, suggestive of a durable immune reaction even after a pathological complete response. Given the increasing use of immune-checkpoint inhibitors in patients with NSCLC or other solid tumors, further clinical evaluation and pathological assessment are warranted to provide a better understanding of such pseudoprogression. (C) 2016 Elsevier Ireland Ltd. All rights reserved.

引用

页码：44 / 48

页数：5

共 15 条

[1]

[Anonymous], ASCO M

[2] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[3] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[4] Pseudoprogression and Immune-Related Response in Solid Tumors [J].

Chiou, Victoria L. ;

Burotto, Mauricio .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (31) :3541-+

[5] Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment [J].

Cohen, Justine V. ;

Alomari, Ahmed K. ;

Vortmeyer, Alexander O. ;

Jilaveanu, Lucia B. ;

Goldberg, Sarah B. ;

Mahajan, Amit ;

Chiang, Veronica L. ;

Kluger, Harriet M. .

CANCER IMMUNOLOGY RESEARCH, 2016, 4 (03) :179-182

[6] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[7] Carcinoembryonic antigen (CEA) as tumor marker in lung cancer [J].

Grunnet, M. ;

Sorensen, J. B. .

LUNG CANCER, 2012, 76 (02) :138-143

[8] CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS [J].

Hodi, F. Stephen ;

Oble, Darryl A. ;

Drappatz, Jan ;

Velazquez, Elsa F. ;

Ramaiya, Nikhil ;

Ramakrishna, Naren ;

Day, Arthur L. ;

Kruse, Andrea ;

Mac Rae, Suzanne ;

Hoos, Axel ;

Mihm, Martin .

NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (09) :557-561

[9] Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients [J].

Hodi, F. Stephen ;

Butler, Marcus ;

Oble, Darryl A. ;

Seiden, Michael V. ;

Haluska, Frank G. ;

Kruse, Andrea ;

MacRae, Suzanne ;

Nelson, Marybeth ;

Canning, Christine ;

Lowy, Israel ;

Korman, Alan ;

Lautz, David ;

Russell, Sara ;

Jaklitsch, Michael T. ;

Ramaiya, Nikhil ;

Chen, Teresa C. ;

Neuberg, Donna ;

Allison, James P. ;

Mihm, Martin C. ;

Dranoff, Glenn .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (08) :3005-3010

[10] Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab [J].

Hodi, F. Stephen ;

Hwu, Wen-Jen ;

Kefford, Richard ;

Weber, Jeffrey S. ;

Daud, Adil ;

Hamid, Omid ;

Patnaik, Amita ;

Ribas, Antoni ;

Robert, Caroline ;

Gangadhar, Tara C. ;

Joshua, Anthony M. ;

Hersey, Peter ;

Dronca, Roxana ;

Joseph, Richard ;

Hille, Darcy ;

Xue, Dahai ;

Li, Xiaoyun Nicole ;

Kang, S. Peter ;

Ebbinghaus, Scot ;

Perrone, Andrea ;

Wolchok, Jedd D. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (13) :1510-+

← 1 2 →